Unum Therapeutics Inc (UMRX) stock has gained 69.50% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives UMRX stock a score of 87 out of a possible 100.
That rank is primarily influenced by a fundamental score of 96. In addition to the average rating from Wall Street analysts, UMRX stock has a mean target price of 6. This means analysts expect the stock to rise 151.05% over the next 12 months. UMRX's rank also includes a long-term technical score of 84. The short-term technical score for UMRX is 79.
What's Happening with UMRX Stock Today
Unum Therapeutics Inc (UMRX) stock has risen 6.22% while the S&P 500 has gained 1.09% as of 11:28 AM on Wednesday, Sep 30. UMRX has gained $0.14 from the previous closing price of $2.25 on volume of 73,800 shares. Over the past year the S&P 500 has risen 14.68% while UMRX has gained 69.50%. UMRX lost -$0.75 per share in the over the last 12 months.
Click Here to get the full Stock Score Report on Unum Therapeutics Inc (UMRX) Stock.
